{"prompt": "['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'All subjects will be given an eDiary for use during the run-in, and treatment period to', 'complete PRO questionnaires and record medical problems experienced during the study.', 'Subjects will be performing slow and forced spirometry at specific visits.', 'In addition, a subset of subjects up to 150 per treatment arm will undergo assessment of', 'their physical activity measured through a physical activity monitor (Actigraph GT9X)', 'worn for 7 days from Screening (Visit 1), for 7 days from Randomisation (Visit 2), 7', 'days from Visit 3, and for 7 days prior to last clinic Visit (Visit 5).', 'There will be a total of 5 clinic visits and one follow-up phone call (Visit 6). The total', 'duration of subject participation in the study will be approximately 29 to 31 weeks', 'consisting of 2 weeks pre-screening if necessary, 4 weeks run-in, 24 week treatment and', 'one week Follow-Up.', 'Subjects will be considered to have completed the study upon completion of the Follow-', 'Up contact by telephone.', 'Treatment Arms and Duration', 'Subjects will be stratified based on long-acting bronchodilator usage during the run-in', '(none, one or 2 long-acting bronchodilators per day) and randomized in a ratio of 1:1:1 to', 'either', 'UMEC/VI inhalation powder (62.5/25 mcg once daily) administered via the', 'ELLIPTA DPI) or', 'UMEC (62.5 mcg once daily) administered via the ELLIPTA DPI or', 'Salmeterol (50 mcg BID) administered via DISKUS', '12']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Study schematic', 'Run-in (4 weeks)', 'UMEC/VI62.5/25mcg (QD)', 'Pre-', 'COPD Meds*', 'Screen', 'R', 'UMEC62.5 mcg (QD)', 'Follow-up phone call', '7 + 3 days', 'Salmeterol 50mcg (BID)', 'V0', 'V1', 'V2', 'V3', 'V4', 'V5', 'V6', 'W4', 'W12', 'W24', '24 Week Treatment Period', '*Inhaled COPD medications including LABAs, LAMAs or LABA/LAMA combination products are', 'allowed in run-in. ICS alone or in combination with a bronchodilator or any exclusionary', 'medications are not allowed.', 'Type and Number of Subjects', 'Approximately 3232 subjects will be screened, such that 2424 subjects will be', 'randomized and approximately 2181 evaluable subjects complete the study.', 'Analysis', 'The primary purpose of this study is to demonstrate improvements in lung function for', 'subjects treated with UMEC/VI compared with UMEC for 24 weeks.', 'The primary endpoint is change from baseline in trough FEV1 at Week 24.', 'The null hypothesis is no difference between treatment groups (HO: T - S = 0), with', 'the alternative hypothesis that there is a difference between treatment groups (H1: T -', 'S + 0), where T is the mean change from baseline for UMEC/VI and S is the mean', 'change from baseline for UMEC.', 'The primary endpoint of mean change from baseline in trough FEV1 at the end of Week', '24 will be analysed using Mixed Models repeated Measures (MMRM) analysis. The', 'MMRM analysis will include measurements at Treatment Weeks 4, 12 and 24. Treatment', 'group (a categorical variable) will be fitted as the explanatory variable with appropriate', 'pre-defined variables, stratum (number of bronchodilators per day during run-in) and', 'baseline values, fitted as covariates. Visit (nominal) will be fitted as a categorical variable', 'and visit-by-baseline and visit-by-treatment interaction terms will be included to allow', 'treatment effects to be estimated at each visit separately. The variance covariance matrix', '13']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'will be assumed to be unstructured (based on previous experience no issues are expected', 'with fitting models with this matrix structure).', 'The estimated treatment differences between UMEC/VI versus UMEC for each endpoint', 'will be presented with the 95% confidence intervals for the difference and the p-value.', '14']\n\n###\n\n", "completion": "END"}